Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearance

Endpoints NewsBMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus

Promega BlogTiny Edits, Big Harvests: How a Massive Mutation Screen Could Transform Crop Engineering

PharmaVoiceChina’s biotech rise sparks new US industry alliance

FierceBiotechStruggling Liminatus pays $320M in stock for CAR-T biotech InnocsAI

Eli LillyLilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling - BioSpace

CellScavenger receptor class F member 2 is an intracellular receptor for hepatitis B virus

CellHarnessing citizen science to contextualize adaptation mechanism discovery

Endpoints NewsLilly’s triple agonist still leads among late-stage obesity assets

Eli LillyExperimental Drug Yields Dramatic Weight Loss - The New York Times

Eli LillyEli Lilly maintains M&A streak with $202m Engage Bio buyout - Pharmaceutical Technology

FierceBiotechInfex, following in Insmed’s footsteps, advances lung disease candidate after clearing phase 2a

Thermo FisherThermo Fisher Scientific’s SWOT analysis: stock navigates growth amid strategic shifts - Investing.com